clofibric acid has been researched along with Obesity in 18 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats." | 3.74 | Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lupp, A | 1 |
| Karge, E | 1 |
| Deufel, T | 1 |
| Oelschlägers, H | 1 |
| Fleck, C | 1 |
| Zambon, A | 1 |
| Marchiori, M | 1 |
| Manzato, E | 1 |
| Ishida, N | 1 |
| Zhao, X | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Cybulska, B | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 2 |
| Wray, R | 1 |
| Toyama, T | 1 |
| Kudo, N | 1 |
| Mitsumoto, A | 1 |
| Kawashima, Y | 1 |
| Császár, A | 1 |
| Moser, M | 1 |
| Falkner, B | 1 |
| Weber, MA | 1 |
| Keilson, LM | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Heike, Z | 1 |
| Gudrun, UM | 1 |
| Frank, RD | 1 |
| Vetter, H | 1 |
| Walger, P | 1 |
| Caira, F | 2 |
| Pacot, C | 2 |
| Bardot, O | 1 |
| Cherkaoui Malki, M | 2 |
| Latruffe, N | 1 |
| Petit, M | 1 |
| Rollin, M | 1 |
| Behechti, N | 1 |
| Grégoire, S | 1 |
| Cavatz, C | 1 |
| Moisant, M | 1 |
| Moreau, C | 1 |
| Silva, JM | 1 |
| Serra e Silva, P | 1 |
| Herbert, JM | 1 |
| Bernat, A | 1 |
| Chatenet-Duchène, L | 1 |
| Mohan, PF | 1 |
| Cleary, MP | 2 |
| Kasiske, B | 1 |
| O'Donnell, MP | 1 |
| Keane, WF | 1 |
6 reviews available for clofibric acid and Obesity
| Article | Year |
|---|---|
[Clock genes regulate circadian rhythm of lipid metabolism and infarction].
Topics: Animals; Biological Clocks; Circadian Rhythm; Clofibric Acid; Humans; Infarction; Ligands; Lipid Met | 2008 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
[Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Topics: Clofibric Acid; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; | 2005 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
Hypertriglyceridemia, the coronary heart disease risk marker "solved".
Topics: Apolipoprotein C-III; Apolipoproteins C; Clinical Trials as Topic; Clofibric Acid; Coronary Disease; | 2005 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
1 trial available for clofibric acid and Obesity
| Article | Year |
|---|---|
Does obesity influence ciprofibrate activity?
Topics: Adult; Aged; Body Mass Index; Clofibric Acid; Female; Fibric Acids; Humans; Hypolipidemic Agents; Ma | 1998 |
11 other studies available for clofibric acid and Obesity
| Article | Year |
|---|---|
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases | 2008 |
Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity?
Topics: Animals; Clofibric Acid; Dietary Fats; Humans; Hypertension; Hypolipidemic Agents; Kidney Diseases; | 2009 |
Regulation of palmitoyl-CoA chain elongation by clofibric acid in the liver of Zucker fa/fa rats.
Topics: Acetyltransferases; Animals; Clofibric Acid; Fatty Acid Elongases; Liver; Male; Obesity; Oleic Acid; | 2005 |
The metabolic syndrome--what is it and how should it be managed?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Multiple benign symmetric lipomatosis--a differential diagnosis of obesity: is there a rationale for fibrate treatment?
Topics: Clofibric Acid; Diagnosis, Differential; Humans; Lipomatosis, Multiple Symmetrical; Male; Middle Age | 2008 |
Transcriptional and post-transcriptional analysis of peroxisomal protein encoding genes from rat treated with an hypolipemic agent, ciprofibrate. Effect of an intermittent treatment and influence of obesity.
Topics: Acyl-CoA Oxidase; Animals; Clofibric Acid; Fibric Acids; Liver; Male; Microbodies; Obesity; Oxidored | 1995 |
Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats.
Topics: Animals; Cholesterol; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Fibric Acids | 1993 |
Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clofibric Acid; Dose-Response Relationshi | 1999 |
Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Clofibrate; Clofibric Acid; Dehydroepiandrosterone; Disease Mod | 1989 |
Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats.
Topics: Adipose Tissue; Animals; Cholesterol; Clofibrate; Clofibric Acid; Lipid Metabolism; Lipids; Liver; M | 1987 |